江苏睿源生物技术

Jiangsu Ruiyuan Biotechnology is a clinical-stage biopharmaceutical company headquartered in the China Medical City of Taizhou, Jiangsu Province. The company is dedicated to the research, development, and commercialization of next-generation immune cell therapies, with a primary focus on CAR-T and TCR-T technologies. Its pipeline includes candidates targeting hematological malignancies and challenging solid tumors such as liver cancer. Ruiyuan Biotech operates advanced GMP-compliant manufacturing facilities to support its clinical development programs. By integrating genetic engineering with cell processing, the company aims to deliver precise and effective treatments for cancer patients. Through strategic collaborations with clinical centers, Ruiyuan Biotech is advancing its pipeline to address significant unmet needs in oncology.